Vicki L. Wheelock, M.D.
Director, Neurology Residency Program
Director, Huntington’s Disease Clinic
Site Investigator, Huntington Study Group
Lawrence J. Ellison Ambulatory Care Center
4860 Y St., Suite 0100
Sacramento, CA 95817
Clinical & Research Interests
Vicki Wheelock is a neurologist specializing in Movement Disorders, with special interests in Huntington’s disease, Parkinson’s disease and ataxia. Dr. Wheelock has expertise in the treatment of Parkinson’s’ disease, including both medical therapies and deep brain stimulation. She has been involved in Huntington’s disease research through membership in the Huntington Study Group (HSG) since 1997, serving as the site investigator for numerous HSG-sponsored clinical studies and trials. As the director of the HDSA center of Excellence at UC Davis since 2001, she leads a multi-disciplinary team providing expert care for patients and families affected by Huntington’s disease. In 2008 Dr. Wheelock initiated a collaboration with stem cell program researcher Dr. Jan Nolta, Director of the UC Davis Institute for Regenerative Cures, leading to a major grant funded by the California Institute of Regenerative Medicine in 2012 to develop an adult stem cell-based therapy to treat Huntington’s disease.
University of Michigan Medical School
Ann Arbor, Michigan
University of Michigan
Ann Arbor, Michigan
William Beaumont Hospital
Royal Oak, Michigan
University of Southern California
Los Angeles, California
American Board of Psychiatry and Neurology, 1990
National Board of Medical Examiners, 1984
Professional MembershipsAmerican Academy of Neurology
Dystonia Medical Research Foundation
Huntington Study Group
Huntington’s Disease Society of America
International Tremor Foundation
Movement Disorder Society
Select Recent Publications
E. Ray Dorsey, MD, MBA1,6; Christopher A. Beck, PhD2; Kristin Darwin, BS1; Paige Nichols, BA1; Alicia F. D. Brocht, MS3; Kevin M. Biglan, MD, MPH4; Ira Shoulson, MD5 ; for the Huntington Study Group COHORT Investigators. Natural History of Huntington’s disease. JAMA Neurol. 2013;70(12):1520-1530.
Olson SD, Pollock K, Kambal A, Cary W, Mitchel GM, Tempkin J, Stewart S, McGee J, Bauer G, Kim HS, Tempkin T, Wheelock V, Annett G, Dunbar G and Nolta J. Genetically Engineered Mesenchymal Stem Cells as a Proposed Therapeutic for Huntington’s Disease. Mol Neurobiol 2012 Feb;45(1):87-98. Epub 2011 Dec 9.
HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network* A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease. JAMA Neurol. 2013;70(1):25.
Dorsey ER; Huntington Study Group COHORT Investigators. Characterization of a large group of individuals with Huntington disease and their relatives enrolled in the COHORT study. PLoS One 2012;7(2):e29522. Epub 2012 Feb 16.
Higginson CI, Wheelock VL, Levine D, Pappas CT, Sigvardt KA. Predictors of HVOT performance in Parkinson’s disease. Appl Neuropsychol. 2011 Jul;18(3):210-5. PMID: 2184622
Wheelock V, Chapter 4, The Motor Disorder, in A Physician’s Guide to Huntington’s Disease, 3rd edition, Huntington’s Disease Society of America, New York, NY 2011.
Wheelock V, Chapter 10, Clinical Trials and Observational Studies in Huntington’s Disease, in A Physician’s Guide to Huntington’s Disease, 3rd edition, Huntington’s Disease Society of America, New York, NY 2011.
Higginson, CI, Wheelock V, Levine D, King D, Pappas CTE and Sigvardt KA. Cognitive Deficits in Essential Tremor Consistent with Frontosubcortical Dysfunction, J Clin Exper Neuropsych, 2008 Feb 15:1-6. [Epub ahead of print]..
Wheelock VL, Tempkin T, Marder K, Nance M, Myers R, Zhao H, Kayson E, Orme C, Shoulson I and the Huntington Study Group. Predictors of nursing home placement in Huntington disease. Neurology 60:998-1001, 2003.